オリゴヌクレオチド複合体：世界市場シェアとランキング、総売上高と需要予測　2025-2031年

オリゴヌクレオチド複合体の世界市場は、2024年には1億6,920万米ドルに達すると推定され、2025～2031年の予測期間中に40.36%のCAGRで成長し、2031年までに17億6,880万米ドルに再調整された規模に達すると予測されています。

本レポートは、オリゴヌクレオチドコンジュゲートの世界市場について、総売上高、主要企業の市場シェア、ランキングに焦点を当て、地域・国別、タイプ別、用途別のオリゴヌクレオチドコンジュゲート分析を含む包括的な分析を提供することを目的としています。

オリゴヌクレオチドコンジュゲート市場の規模、推定値、および予測は、2024年を基準年として売上高（百万ドル）ベースで提供され、2020年から2031年までの実績および予測データも含まれています。定量分析と定性分析の両方を用いて、読者が事業／成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、オリゴヌクレオチドコンジュゲートに関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

Report Overview

The global market for Oligonucleotide Conjugates was estimated to be worth US$ 169.2 million in 2024 and is forecast to a readjusted size of US$ 1,768.8 million by 2031 with a CAGR of 40.36% during the forecast period 2025-2031.

North American market for Oligonucleotide Conjugates was valued at $ 72.98 million in 2024 and will reach $ 719.9 million by 2031, at a CAGR of 39.28% during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotide Conjugates was valued at $ 43.89 million in 2024 and will reach $ 542.67 million by 2031, at a CAGR of 43.72% during the forecast period of 2025 through 2031.

Europe market for Oligonucleotide Conjugates was valued at $ 45.29 million in 2024 and will reach $ 443.26 million by 2031, at a CAGR of 38.89% during the forecast period of 2025 through 2031.

The global key companies of Oligonucleotide Conjugates include WuXi TIDES, Bachem, Lonza, BioSpring, GenScript, Medtide (CPC Scientific), Pharmaron, Bio-Synthesis Inc, and Kaneka Corporation (Eurogentec), etc. in 2024, the global five largest players hold a share approximately 72% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Conjugates, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Conjugates by region & country, by Type, and by Application.

The Oligonucleotide Conjugates market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Conjugates.

Market Segmentation

By Company

•  WuXi TIDES
• Bachem
• Lonza
• BioSpring
• GenScript
• Medtide(CPC Scientific)
• Kaneka Corporation(Eurogentec)
• Olon(GTP Bioways)
• Abzena
• 3PBIOVIAN
• Bio-Synthesis Inc
• ChemExpress
• Creative Biolabs
• HitGen
• Pharmaron
• Suzhou Biosyntech
• Creative Biogene (IntegrateRNA)

Segment by Type

• Oligonucleotide-Peptide
• Oligonucleotide-Antibody
• Oligonucleotide-GalNAc
• Oligonucleotide-Lipid
• Other

Segment by Application

• Gene Therapy
• Drug Delivery
• Vaccine Development

By Region

North America

• United States
• Canada

Asia-Pacific

• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia-Pacific

Europe

• Germany
• U.K.
• Switzerland
• Belgium
• France
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oligonucleotide Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:  Revenue of Oligonucleotide Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6:  Revenue of Oligonucleotide Conjugates in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview           1

1.1 Oligonucleotide Conjugates Product Introduction      1

1.2 Global Oligonucleotide Conjugates Market Size Forecast (2020-2031)            1

1.3 Oligonucleotide Conjugates Market Trends & Drivers 3

1.3.1 Oligonucleotide Conjugates Industry Trends          3

1.3.2 Oligonucleotide Conjugates Market Drivers & Opportunity    4

1.3.3 Oligonucleotide Conjugates Market Challenges      5

1.3.4 Oligonucleotide Conjugates Market Restraints       6

1.4 Assumptions and Limitations       6

1.5 Study Objectives         7

1.6 Years Considered        8

2 Competitive Analysis by Company  9

2.1 Global Oligonucleotide Conjugates Players Revenue Ranking (2024)            9

2.2 Global Oligonucleotide Conjugates Revenue by Company (2020-2025)            10

2.3 Key Companies Oligonucleotide Conjugates Product Offered   12

2.4 Key Companies Time to Establish 13

2.5 Oligonucleotide Conjugates Market Competitive Analysis        14

2.5.1 Oligonucleotide Conjugates Market Concentration Rate (2020-2025)            14

2.5.2 Global 5 and 10 Largest Companies by Oligonucleotide Conjugates Revenue in 2024   16

2.5.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Conjugates as of 2024) 17

2.6 Mergers & Acquisitions, Expansion           19

3 Segmentation by Type     22

3.1 Introduction by Type     22

3.1.1 Oligonucleotide-Peptide          22

3.1.2 Oligonucleotide-Antibody        22

3.1.3 Oligonucleotide-GalNAc           23

3.1.4 Oligonucleotide-Lipid  24

3.1.5 Other         25

3.2 Global Oligonucleotide Conjugates Sales Value by Type         26

3.2.1 Global Oligonucleotide Conjugates Sales Value by Type (2020 VS 2024 VS 2031)            26

3.2.2 Global Oligonucleotide Conjugates Sales Value, by Type (2020-2031)            28

3.2.3 Global Oligonucleotide Conjugates Sales Value, by Type (%) (2020-2031)    29

4 Segmentation by Application          30

4.1 Introduction by Application          30

4.1.1 Gene Therapy           30

4.1.2 Drug Delivery           30

4.1.3 Vaccine Development 30

4.2 Global Oligonucleotide Conjugates Sales Value by Application  31

4.2.1 Global Oligonucleotide Conjugates Sales Value by Application (2020 VS 2024 VS 2031)    31

4.2.2 Global Oligonucleotide Conjugates Sales Value, by Application (2020-2031)    33

4.2.3 Global Oligonucleotide Conjugates Sales Value, by Application (%) (2020-2031)       33

5 Segmentation by Region   35

5.1 Global Oligonucleotide Conjugates Sales Value by Region       35

5.1.1 Global Oligonucleotide Conjugates Sales Value by Region: 2020 VS 2024 VS 2031     35

5.1.2 Global Oligonucleotide Conjugates Sales Value by Region (2020-2025)            36

5.1.3 Global Oligonucleotide Conjugates Sales Value by Region (2026-2031)            36

5.1.4 Global Oligonucleotide Conjugates Sales Value by Region (%), (2020-2031)    37

5.2 North America 38

5.2.1 North America Oligonucleotide Conjugates Sales Value, 2020-2031            38

5.2.2 North America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031     39

5.3 Europe          40

5.3.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031 40

5.3.2 Europe Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031 41

5.4 Asia Pacific    42

5.4.1 Asia Pacific Oligonucleotide Conjugates Sales Value, 2020-2031            42

5.4.2 Asia Pacific Oligonucleotide Conjugates Sales Value by Region (%), 2024 VS 2031     43

5.5 South America 44

5.5.1 South America Oligonucleotide Conjugates Sales Value, 2020-2031            44

5.5.2 South America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031     45

6 Segmentation by Key Countries/Regions     46

6.1 Key Countries/Regions Oligonucleotide Conjugates Sales Value Growth Trends, 2020 VS 2024 VS 2031      46

6.2 Key Countries/Regions Oligonucleotide Conjugates Sales Value, 2020-2031     47

6.3 United States  51

6.3.1 United States Oligonucleotide Conjugates Sales Value, 2020-2031            51

6.3.2 United States Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     52

6.3.3 United States Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031     53

6.4 Europe          54

6.4.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031 54

6.4.2 Europe Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     55

6.4.3 Europe Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031     56

6.5 China 57

6.5.1 China Oligonucleotide Conjugates Sales Value, 2020-2031  57

6.5.2 China Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     58

6.5.3 China Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031     59

6.6 Japan            60

6.6.1 Japan Oligonucleotide Conjugates Sales Value, 2020-2031  60

6.6.2 Japan Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     61

6.6.3 Japan Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031     62

6.7 South Korea   63

6.7.1 South Korea Oligonucleotide Conjugates Sales Value, 2020-2031            63

6.7.2 South Korea Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 64

6.7.3 South Korea Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031     65

6.8 Australia        66

6.8.1 Australia Oligonucleotide Conjugates Sales Value, 2020-2031            66

6.8.2 Australia Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     67

6.8.3 Australia Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 68

6.9 India 69

6.9.1 India Oligonucleotide Conjugates Sales Value, 2020-2031    69

6.9.2 India Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     70

6.9.3 India Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031     71

7 Company Profiles           72

7.1 WuXi TIDES    72

7.1.1 WuXi TIDES Profile    72

7.1.2 WuXi TIDES Main Business       73

7.1.3 WuXi TIDES Oligonucleotide Conjugates Products, Services and Solutions 74

7.1.4 WuXi TIDES Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)       74

7.1.5 WuXi TIDES Recent Developments         75

7.2 Bachem         75

7.2.1 Bachem Profile         75

7.2.2 Bachem Main Business 76

7.2.3 Bachem Oligonucleotide Conjugates Products, Services and Solutions            77

7.2.4 Bachem Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)    77

7.2.5 Bachem Recent Developments  77

7.3 Lonza           78

7.3.1 Lonza Profile 78

7.3.2 Lonza Main Business  79

7.3.3 Lonza Oligonucleotide Conjugates Products, Services and Solutions            79

7.3.4 Lonza Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)    80

7.3.5 Lonza Recent Developments     80

7.4 BioSpring       81

7.4.1 BioSpring Profile        81

7.4.2 BioSpring Main Business          81

7.4.3 BioSpring Oligonucleotide Conjugates Products, Services and Solutions            82

7.4.4 BioSpring Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)    83

7.4.5 BioSpring Recent Developments 83

7.5 GenScript       84

7.5.1 GenScript Profile       84

7.5.2 GenScript Main Business          85

7.5.3 GenScript Oligonucleotide Conjugates Products, Services and Solutions            85

7.5.4 GenScript Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)    86

7.6 Medtide (CPC Scientific) 86

7.6.1 Medtide (CPC Scientific) Profile 86

7.6.2 Medtide (CPC Scientific) Main Business   87

7.6.3 Medtide (CPC Scientific) Oligonucleotide Conjugates Products, Services and Solutions       88

7.6.4 Medtide (CPC Scientific) Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025)           89

7.6.5 Medtide (CPC Scientific) Recent Developments     89

7.7 Kaneka Corporation (Eurogentec) 89

7.7.1 Kaneka Corporation (Eurogentec) Profile 89

7.7.2 Kaneka Corporation (Eurogentec) Main Business   90

7.7.3 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Products, Services and Solutions       91

7.7.4 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)           91

7.8 Olon (GTP Bioways)      92

7.8.1 Olon (GTP Bioways) Profile      92

7.8.2 Olon (GTP Bioways) Main Business        92

7.8.3 Olon (GTP Bioways) Oligonucleotide Conjugates Products, Services and Solutions 93

7.8.4 Olon (GTP Bioways) Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)    94

7.8.5 Olon (GTP Bioways) Recent Developments           94

7.9 Abzena         94

7.9.1 Abzena Profile          95

7.9.2 Abzena Main Business 95

7.9.3 Abzena Oligonucleotide Conjugates Products, Services and Solutions            96

7.9.4 Abzena Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)    96

7.10 3PBIOVIAN   97

7.10.1 3PBIOVIAN Profile    97

7.10.2 3PBIOVIAN Main Business      98

7.10.3 3PBIOVIAN Oligonucleotide Conjugates Products, Services and Solutions 98

7.10.4 3PBIOVIAN Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025)       99

7.11 Bio-Synthesis Inc       99

7.11.1 Bio-Synthesis Inc Profile       99

7.11.2 Bio-Synthesis Inc Main Business          100

7.11.3 Bio-Synthesis Inc Oligonucleotide Conjugates Products, Services and Solutions 100

7.11.4 Bio-Synthesis Inc Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)       102

7.12 ChemExpress            102

7.12.1 ChemExpress Profile 102

7.12.2 ChemExpress Main Business   103

7.12.3 ChemExpress Oligonucleotide Conjugates Products, Services and Solutions 104

7.12.4 ChemExpress Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)       104

7.13 Creative Biolabs         105

7.13.1 Creative Biolabs Profile         105

7.13.2 Creative Biolabs Main Business            105

7.13.3 Creative Biolabs Oligonucleotide Conjugates Products, Services and Solutions 106

7.13.4 Creative Biolabs Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)       108

7.14 HitGen         108

7.14.1 HitGen Profile         108

7.14.2 HitGen Main Business 109

7.14.3 HitGen Oligonucleotide Conjugates Products, Services and Solutions            109

7.14.4 HitGen Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)    110

7.15 Pharmaron    110

7.15.1 Pharmaron Profile    111

7.15.2 Pharmaron Main Business       111

7.15.3 Pharmaron Oligonucleotide Conjugates Products, Services and Solutions 113

7.15.4 Pharmaron Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025)       113

7.16 Suzhou Biosyntech     114

7.16.1 Suzhou Biosyntech Profile      114

7.16.2 Suzhou Biosyntech Main Business        114

7.16.3 Suzhou Biosyntech Oligonucleotide Conjugates Products, Services and Solutions 115

7.16.4 Suzhou Biosyntech Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025)    116

7.17 Creative Biogene (IntegrateRNA)           116

7.17.1 Creative Biogene (IntegrateRNA) Profile 116

7.17.2 Creative Biogene (IntegrateRNA) Main Business  117

7.17.3 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Products, Services and Solutions       117

7.17.4 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)           118

8 Industry Chain Analysis    119

8.1 Oligonucleotide Conjugates Industrial Chain 119

8.2 Oligonucleotide Conjugates Upstream Analysis        119

8.2.1 Key Raw Materials     119

8.2.2 Raw Materials Key Suppliers     120

8.3 Midstream Analysis       120

8.4 Downstream Analysis (Customers Analysis)            121

9 Research Findings and Conclusion   123

10 Appendix        125

10.1 Research Methodology 125

10.1.1 Methodology/Research Approach        125

10.1.2 Data Source           128

10.2 Author Details           131

10.3 Disclaimer    132

Tables and Figures

Table 1. Oligonucleotide Conjugates Market Trends       3

Table 2. Oligonucleotide Conjugates Market Drivers & Opportunity 4

Table 3. Oligonucleotide Conjugates Market Challenges  5

Table 4. Oligonucleotide Conjugates Market Restraints   6

Table 5. Global Oligonucleotide Conjugates Revenue by Company (2020-2025) & (US$ Million)        10

Table 6. Global Oligonucleotide Conjugates Revenue Market Share by Company (2020-2025)      11

Table 7. Key Companies Oligonucleotide Conjugates Product Type 12

Table 8. Key Companies Time to Establish       13

Table 9. Global Oligonucleotide Conjugates Companies Market Concentration Ratio (CR5 and HHI)           15

Table 10. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Conjugates as of 2024)            17

Table 11. Mergers & Acquisitions, Expansion Plans        19

Table 12. Global Oligonucleotide Conjugates Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million) 27

Table 13. Global Oligonucleotide Conjugates Sales Value by Type (2020-2025) & (US$ Million)        28

Table 14. Global Oligonucleotide Conjugates Sales Value by Type (2026-2031) & (US$ Million)        28

Table 15. Global Oligonucleotide Conjugates Sales Market Share in Value by Type (2020-2025)           29

Table 16. Global Oligonucleotide Conjugates Sales Market Share in Value by Type (2026-2031)           29

Table 17. Global Oligonucleotide Conjugates Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)       32

Table 18. Global Oligonucleotide Conjugates Sales Value by Application (2020-2025) & (US$ Million)           33

Table 19. Global Oligonucleotide Conjugates Sales Value by Application (2026-2031) & (US$ Million)           33

Table 20. Global Oligonucleotide Conjugates Sales Market Share in Value by Application (2020-2025)    33

Table 21. Global Oligonucleotide Conjugates Sales Market Share in Value by Application (2026-2031)    34

Table 22. Global Oligonucleotide Conjugates Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)   35

Table 23. Global Oligonucleotide Conjugates Sales Value by Region (2020-2025) & (US$ Million)        36

Table 24. Global Oligonucleotide Conjugates Sales Value by Region (2026-2031) & (US$ Million)        36

Table 25. Global Oligonucleotide Conjugates Sales Value by Region (2020-2025) & (%)        37

Table 26. Global Oligonucleotide Conjugates Sales Value by Region (2026-2031) & (%)        37

Table 27. Key Countries/Regions Oligonucleotide Conjugates Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031  46

Table 28. Key Countries/Regions Oligonucleotide Conjugates Sales Value, (2020-2025) & (US$ Million)           47

Table 29. Key Countries/Regions Oligonucleotide Conjugates Sales Value, (2026-2031) & (US$ Million)           48

Table 30. WuXi TIDES Basic Information List    72

Table 31. WuXi TIDES Description and Business Overview           73

Table 32. WuXi TIDES Oligonucleotide Conjugates Products, Services and Solutions 74

Table 33. Revenue (US$ Million) in Oligonucleotide Conjugates Business of WuXi TIDES (2020-2025)   74

Table 34. WuXi TIDES Recent Developments    75

Table 35. Bachem Basic Information List         75

Table 36. Bachem Description and Business Overview    76

Table 37. Bachem Oligonucleotide Conjugates Products, Services and Solutions 77

Table 38. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Bachem (2020-2025)        77

Table 39. Bachem Recent Developments         77

Table 40. Lonza Basic Information List           78

Table 41. Lonza Description and Business Overview      79

Table 42. Lonza Oligonucleotide Conjugates Products, Services and Solutions            79

Table 43. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Lonza (2020-2025)          80

Table 44. Lonza Recent Developments           80

Table 45. BioSpring Basic Information List       81

Table 46. BioSpring Description and Business Overview  81

Table 47. BioSpring Oligonucleotide Conjugates Products, Services and Solutions 82

Table 48. Revenue (US$ Million) in Oligonucleotide Conjugates Business of BioSpring (2020-2025)      83

Table 49. BioSpring Recent Developments       83

Table 50. GenScript Basic Information List      84

Table 51. GenScript Description and Business Overview 85

Table 52. GenScript Oligonucleotide Conjugates Products, Services and Solutions 85

Table 53. Revenue (US$ Million) in Oligonucleotide Conjugates Business of GenScript (2020-2025)     86

Table 54. Medtide (CPC Scientific) Basic Information List            86

Table 55. Medtide (CPC Scientific) Description and Business Overview            87

Table 56. Medtide (CPC Scientific) Oligonucleotide Conjugates Products, Services and Solutions       88

Table 57. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Medtide (CPC Scientific) (2022-2025)           89

Table 58. Medtide (CPC Scientific) Recent Developments            89

Table 59. Kaneka Corporation (Eurogentec) Basic Information List 89

Table 60. Kaneka Corporation (Eurogentec) Description and Business Overview 90

Table 61. Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Products, Services and Solutions      91

Table 62. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Kaneka Corporation (Eurogentec) (2020-2025)           91

Table 63. Olon (GTP Bioways) Basic Information List     92

Table 64. Olon (GTP Bioways) Description and Business Overview 92

Table 65. Olon (GTP Bioways) Oligonucleotide Conjugates Products, Services and Solutions       93

Table 66. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Olon (GTP Bioways) (2023-2025)    94

Table 67. Olon (GTP Bioways) Recent Developments     94

Table 68. Abzena Basic Information List         95

Table 69. Abzena Description and Business Overview    95

Table 70. Abzena Oligonucleotide Conjugates Products, Services and Solutions 96

Table 71. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Abzena (2020-2025)        96

Table 72. 3PBIOVIAN Basic Information List     97

Table 73. 3PBIOVIAN Description and Business Overview            98

Table 74. 3PBIOVIAN Oligonucleotide Conjugates Products, Services and Solutions 98

Table 75. Revenue (US$ Million) in Oligonucleotide Conjugates Business of 3PBIOVIAN (2022-2025)    99

Table 76. Bio-Synthesis Inc Basic Information List        99

Table 77. Bio-Synthesis Inc Description and Business Overview    100

Table 78. Bio-Synthesis Inc Oligonucleotide Conjugates Products, Services and Solutions       100

Table 79. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Bio-Synthesis Inc (2020-2025)       102

Table 80. ChemExpress Basic Information List 102

Table 81. ChemExpress Description and Business Overview        103

Table 82. ChemExpress Oligonucleotide Conjugates Products, Services and Solutions 104

Table 83. Revenue (US$ Million) in Oligonucleotide Conjugates Business of ChemExpress (2023-2025) 104

Table 84. Creative Biolabs Basic Information List          105

Table 85. Creative Biolabs Description and Business Overview     105

Table 86. Creative Biolabs Oligonucleotide Conjugates Products, Services and Solutions 106

Table 87. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Creative Biolabs (2020-2025)         108

Table 88. HitGen Basic Information List          108

Table 89. HitGen Description and Business Overview     109

Table 90. HitGen Oligonucleotide Conjugates Products, Services and Solutions            109

Table 91. Revenue (US$ Million) in Oligonucleotide Conjugates Business of HitGen (2023-2025)         110

Table 92. Pharmaron Basic Information List     111

Table 93. Pharmaron Description and Business Overview 111

Table 94. Pharmaron Oligonucleotide Conjugates Products, Services and Solutions 113

Table 95. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Pharmaron (2024-2025)    113

Table 96. Suzhou Biosyntech Basic Information List       114

Table 97. Suzhou Biosyntech Description and Business Overview  114

Table 98. Suzhou Biosyntech Oligonucleotide Conjugates Products, Services and Solutions       115

Table 99. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Suzhou Biosyntech (2024-2025)      116

Table 100. Creative Biogene (IntegrateRNA) Basic Information List            116

Table 101. Creative Biogene (IntegrateRNA) Description and Business Overview 117

Table 102. Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Products, Services and Solutions      117

Table 103. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Creative Biogene (IntegrateRNA) (2020-2025)            118

Table 104. Key Raw Materials Lists   119

Table 105. Raw Materials Key Suppliers Lists  120

Table 106. Oligonucleotide Conjugates Downstream Customers    121

Table 107. Research Programs/Design for This Report  125

Table 108. Key Data Information from Secondary Sources          129

Table 109. Key Data Information from Primary Sources  130

List of Figures

Figure 1. Global Oligonucleotide Conjugates Sales Value, 2020 VS 2024 VS 2031 (US$ Million) 2

Figure 2. Global Oligonucleotide Conjugates Sales Value (2020-2031) & (US$ Million)        2

Figure 3. Oligonucleotide Conjugates Report Years Considered     8

Figure 4. Global Oligonucleotide Conjugates Players Revenue Ranking (2024) & (US$ Million)     9

Figure 5. The 5 Largest Companies in the World: Market Share by Oligonucleotide Conjugates Revenue in 2024   16

Figure 6. The 10 Largest Companies in the World: Market Share by Oligonucleotide Conjugates Revenue in 2024   17

Figure 7. Oligonucleotide Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 19

Figure 8. Oligonucleotide-Peptide Picture        22

Figure 9. Oligonucleotide-Antibody Picture      23

Figure 10. Oligonucleotide-GalNAc Picture      24

Figure 11. Oligonucleotide-Lipid Picture          25

Figure 12. Oligonucleotide-Aptamer Picture     25

Figure 13. Global Oligonucleotide Conjugates Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)        26

Figure 14. Global Oligonucleotide Conjugates Sales Value Market Share by Type, 2024 & 2031          27

Figure 15. Global Oligonucleotide Conjugates Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)      31

Figure 16. Global Oligonucleotide Conjugates Sales Value Market Share by Application, 2024 & 2031   32

Figure 17. North America Oligonucleotide Conjugates Sales Value (2020-2031) & (US$ Million)        38

Figure 18. North America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031           39

Figure 19. Europe Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        40

Figure 20. Europe Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031     41

Figure 21. Asia Pacific Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)     42

Figure 22. Asia Pacific Oligonucleotide Conjugates Sales Value by Region (%), 2024 VS 2031     43

Figure 23. South America Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        44

Figure 24. South America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031           45

Figure 25. Key Countries/Regions Oligonucleotide Conjugates Sales Value (%), (2020-2031) 50

Figure 26. United States Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        51

Figure 27. United States Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     52

Figure 28. United States Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031         53

Figure 29. Europe Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        54

Figure 30. Europe Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 55

Figure 31. Europe Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031     56

Figure 32. China Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        57

Figure 33. China Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 58

Figure 34. China Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031     59

Figure 35. Japan Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        60

Figure 36. Japan Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 61

Figure 37. Japan Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031     62

Figure 38. South Korea Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        63

Figure 39. South Korea Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     64

Figure 40. South Korea Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031           65

Figure 41. Australia Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        66

Figure 42. Australia Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031     67

Figure 43. Australia Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031           68

Figure 44. India Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)        69

Figure 45. India Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 70

Figure 46. India Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031     71

Figure 47. Oligonucleotide Conjugates Industrial Chain    119

Figure 48. Bottom-up and Top-down Approaches for This Report 127

Figure 49. Data Triangulation           128

Figure 50. Key Executives Interviewed           130

QYResearchは広範な市場を対象にし、多様な市場調査レポートを出版している中国北京に本社をおく市場調査会社です。QYResearch出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

QYResearch 出版レポート一覧

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイル閲覧可のライセンスです。
    • 提供ファイルはPDFファイルです。
    • 納品ファイルは印刷可、コピー＆ペースト可。
  • マルチユーザライセンス
    • 同一企業内10名までレポートファイルの閲覧可のライセンスです。
    • 提供ファイルはPDFとExcelファイルです。
    • 納品ファイルは印刷可、コピー＆ペースト可。
  • エンタープライズライセンス
    • 同一企業および関連会社内において人数無制限でレポートファイルの閲覧可のライセンスです。
    • 提供ファイルはPDFとExcelファイルです。
    • 納品ファイルは印刷可、コピー＆ペースト可。
• 納期
  • 既刊レポート：ご注文後3営業日以内
  • オンデマンドレポート：通常7営業日前後

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。